Skip to main content
Erschienen in: Diseases of the Colon & Rectum 11/2004

01.11.2004 | Original Contributions

Evaluation of Prognosis for Malignant Rectal Gastrointestinal Stromal Tumor by Clinical Parameters and Immunohistochemical Staining

verfasst von: Chung Rong Changchien, M.D., Meng-Chi Wu, M.D., Wen-Sy Tasi, M.D., Ph.D., Reiping Tang, M.D., Jy-Ming Chiang, M.D., Jinn-Shiun Chen, M.D., Shiu-Feng Huang, M.D., Jeng-Yi Wang, M.D., Chien-Yuh Yeh, M.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 11/2004

Einloggen, um Zugang zu erhalten

PURPOSE

The aim of this study was to identify associated prognostic factors influencing the outcome of curative resection of rectal gastrointestinal stromal tumor.

PATIENTS AND METHODS

Diagnostic immunohistochemical staining with CD34, CD117, S-100, desmin, and muscle-specific actin was performed in 46 consecutive patients with previously diagnosed rectal leiomyosarcoma who underwent curative resection from 1979 to 1999. CD44, Bcl-2, P53, and Ki-67 staining were performed on tumors rediagnosed as gastrointestinal stromal tumor for the prognostic evaluation.

RESULTS

There were 42 (91.3 percent) patients with rectal gastrointestinal stromal tumor (18 females and 24 males; mean age, 58.4 years). Twenty-nine patients underwent radical surgical resections, such as abdominoperineal resection or low anterior resection, whereas the other 13 patients underwent wide local excision, such as transrectal excision or Kraske’s operation. Sixteen tumors were classified as high-grade gastrointestinal stromal tumors, and 26 as low-grade. No tumor had a positive P53 stain. Twenty-seven patients (64.3 percent) developed recurrence or metastasis postoperatively (median follow-up, 52 months). The one-year, two-year, and five-year disease-free survival rates were 90.2 percent, 76.7 percent, and 43.9 percent, respectively. Of these patients with recurrence, subsequent resections in 12 patients with local recurrence, transarterial tumor embolism or STI-571 chemotherapies in 3 patients with distant mestastases were performed. The one-year, two-year, and five-year overall survival rates were 97.4 percent, 94.3 percent, and 83.7 percent, respectively. Bcl-2 (P = 0.007) and histologic grade (P = 0.05) in disease-free survival analysis and age <50 years (P = 0.03) and tumor size >5 cm (P = 0.02) in overall survival analysis were independent prognostic factors. The group with wide local excision had a higher local recurrence rate than that of the radical resection group (77 percent vs. 31 percent, P = 0.006), despite smaller tumors (4.5 vs. 7.2 cm, P = 0.05). There was no difference in the incidence of distant metastasis between the two groups.

CONCLUSION

Younger age (<50 years), higher histologic tumor grade, positive Bcl-2 status, and larger tumors (>5 cm) were factors associated with significantly poorer prognoses for rectal gastrointestinal stromal tumor. Radical resection was superior to wide local excision in the prevention of local recurrence, but not that of distant metastases.
Literatur
1.
Zurück zum Zitat Diamante, M, Bacon, HE 1967Leiomyosarcoma of the rectum: report of a caseDis Colon Rectum1034751PubMed Diamante, M, Bacon, HE 1967Leiomyosarcoma of the rectum: report of a caseDis Colon Rectum1034751PubMed
2.
Zurück zum Zitat Somervell, JL, Mayer, PF 1971Lejomyosarcoma of the rectumBr J Surg581446PubMed Somervell, JL, Mayer, PF 1971Lejomyosarcoma of the rectumBr J Surg581446PubMed
3.
Zurück zum Zitat Khalifa, AA, Bong, WL, Rao, VK, Williams, MJ 1986Leimyosarcoma of the rectum: report of a case and review of the literatureDis Colon Rectum2942732PubMed Khalifa, AA, Bong, WL, Rao, VK, Williams, MJ 1986Leimyosarcoma of the rectum: report of a case and review of the literatureDis Colon Rectum2942732PubMed
4.
Zurück zum Zitat Randleman, CD,Jr, Wolff, BG, Dozois, RR, Spencer, RJ, Weiland, LH, Ilstrup, DM 1989Leiomyosarcoma of the rectum and anus: a series of 22 casesInt J Colorect Dis4916 Randleman, CD,Jr, Wolff, BG, Dozois, RR, Spencer, RJ, Weiland, LH, Ilstrup, DM 1989Leiomyosarcoma of the rectum and anus: a series of 22 casesInt J Colorect Dis4916
5.
Zurück zum Zitat Vandoni, RE, Givel, JC, Essinger, AR 1992Rectal leiomyosarcoma: acute presentation after local injuryEur J Surg1583836PubMed Vandoni, RE, Givel, JC, Essinger, AR 1992Rectal leiomyosarcoma: acute presentation after local injuryEur J Surg1583836PubMed
6.
Zurück zum Zitat Labow, SB, Hoexter, B 1977Leiomyosarcoma of the rectum: radical vs. conservative therapy and report of three casesDis Colon Rectum206035PubMed Labow, SB, Hoexter, B 1977Leiomyosarcoma of the rectum: radical vs. conservative therapy and report of three casesDis Colon Rectum206035PubMed
7.
Zurück zum Zitat Watanabe, H, Jass, JR, Sobin, LH 1990Histological typing of esophageal and gastric tumors, WHO international classification of tumors2nd edSpringer-VerlagNew York Watanabe, H, Jass, JR, Sobin, LH 1990Histological typing of esophageal and gastric tumors, WHO international classification of tumors2nd edSpringer-VerlagNew York
8.
Zurück zum Zitat Ming, SC, Goldman, H 1998Pathology of the gastrointestinal tract2nd edWilliams and WilkinsBaltimore36172 Ming, SC, Goldman, H 1998Pathology of the gastrointestinal tract2nd edWilliams and WilkinsBaltimore36172
9.
Zurück zum Zitat Miettinen, M, Sarlomo-Rikala, M, Lasota, J 1999Gastrointestinal stromal tumors: recent advances in understanding of their biologyHum Pathol30121320CrossRefPubMed Miettinen, M, Sarlomo-Rikala, M, Lasota, J 1999Gastrointestinal stromal tumors: recent advances in understanding of their biologyHum Pathol30121320CrossRefPubMed
10.
Zurück zum Zitat Maeda, H, Yamagata, A, Nishikawa, S, et al. 1992Requirement of c-kit for development of intestinal pacemaker systemDevelopment11636975PubMed Maeda, H, Yamagata, A, Nishikawa, S,  et al. 1992Requirement of c-kit for development of intestinal pacemaker systemDevelopment11636975PubMed
11.
Zurück zum Zitat Sanders, KM 1996A case of interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tractGatroenterology111492515 Sanders, KM 1996A case of interstitial cells of Cajal as pacemakers and mediators of neurotransmission in the gastrointestinal tractGatroenterology111492515
12.
Zurück zum Zitat Bodey, B, Bodey, B,Jr, Kaiser, HE 1997Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular networkIn Vivo1135170PubMed Bodey, B, Bodey, B,Jr, Kaiser, HE 1997Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular networkIn Vivo1135170PubMed
13.
Zurück zum Zitat Eaves, C, Miller, C, Cashman, J, et al. 1997Hematopoietic stem cells: inferences from in vivo assays Stem Cells15 (Suppl 1)15 Eaves, C, Miller, C, Cashman, J,  et al. 1997Hematopoietic stem cells: inferences from in vivo assays Stem Cells15 (Suppl 1)15
14.
Zurück zum Zitat Perrotti, D, Bellon, T, Trotta, R, Martinez, R, Calabretta, B 1996A cell proliferation-dependent multiprotein complex NC-3A positively regulates the CD34 promoter via a TCATTT-containing elementBlood88333648PubMed Perrotti, D, Bellon, T, Trotta, R, Martinez, R, Calabretta, B 1996A cell proliferation-dependent multiprotein complex NC-3A positively regulates the CD34 promoter via a TCATTT-containing elementBlood88333648PubMed
15.
Zurück zum Zitat Miettinen, M, Virolainen, M, Sarlomo-Rikala, M 1995Gastrointestinal stromal tumors–value of CD34 antigen in their identification and separation from true leiomyomas and schwannomasAm J Surg Pathol1920716PubMed Miettinen, M, Virolainen, M, Sarlomo-Rikala, M 1995Gastrointestinal stromal tumors–value of CD34 antigen in their identification and separation from true leiomyomas and schwannomasAm J Surg Pathol1920716PubMed
16.
Zurück zum Zitat Rudzki, Z, Jothy, S 1997CD44 and the adhesion of neoplastic cellsMol Pathol505771PubMed Rudzki, Z, Jothy, S 1997CD44 and the adhesion of neoplastic cellsMol Pathol505771PubMed
17.
Zurück zum Zitat Goodison, S, Tarin, D 1998Current status of CD44 variant isoforms as cancer diagnostic markersHistopathology3216CrossRefPubMed Goodison, S, Tarin, D 1998Current status of CD44 variant isoforms as cancer diagnostic markersHistopathology3216CrossRefPubMed
18.
Zurück zum Zitat Rao, UN, Finkelstein, SD, Jones, MW 1999Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomaMod Pathol1210019PubMed Rao, UN, Finkelstein, SD, Jones, MW 1999Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomaMod Pathol1210019PubMed
19.
20.
Zurück zum Zitat Yeh, C-Y, Chen, H-H, Tang, R, Tasi, W-S, Lin, P-Y, Wang, J-Y 2000Surgical outcome after curative resection of rectal leiomyosarcomaDis Colon Rectum43151721PubMed Yeh, C-Y, Chen, H-H, Tang, R, Tasi, W-S, Lin, P-Y, Wang, J-Y 2000Surgical outcome after curative resection of rectal leiomyosarcomaDis Colon Rectum43151721PubMed
21.
Zurück zum Zitat Cox, DR 1972Regression models and life tablesJR Stat Soc34187220 Cox, DR 1972Regression models and life tablesJR Stat Soc34187220
22.
Zurück zum Zitat Pierie, JP, Choudry, U, Muzikansky, A, Yeap, BY, Souba, WW, Ott, MJ 2001The effect of surgery and grade on outcome of gastrointestinal stromal tumorsArch Surg1363839CrossRefPubMed Pierie, JP, Choudry, U, Muzikansky, A, Yeap, BY, Souba, WW, Ott, MJ 2001The effect of surgery and grade on outcome of gastrointestinal stromal tumorsArch Surg1363839CrossRefPubMed
23.
Zurück zum Zitat Appelman, HD, Helwig, EB 1997Sarcoma of the stomachAm J Clin Pathol67210 Appelman, HD, Helwig, EB 1997Sarcoma of the stomachAm J Clin Pathol67210
24.
Zurück zum Zitat Appelman, HD, Helwig, EB 1997Cellular leiomyomas of the stomach in 49 patientsArch Pathol Lab Med1013737 Appelman, HD, Helwig, EB 1997Cellular leiomyomas of the stomach in 49 patientsArch Pathol Lab Med1013737
25.
Zurück zum Zitat Akwari, OE, Dozois, RR, Weiland, LH, Beahrs, OH 1978Leiomyosarcoma of the small and large bowelCancer42137584PubMed Akwari, OE, Dozois, RR, Weiland, LH, Beahrs, OH 1978Leiomyosarcoma of the small and large bowelCancer42137584PubMed
26.
Zurück zum Zitat Shiu, MH, Farr, GH, Papachristou, DN, Hajdu, SI 1982Myosarcoma of the stomach: natural history, prognostic factors and managementCancer4917787PubMed Shiu, MH, Farr, GH, Papachristou, DN, Hajdu, SI 1982Myosarcoma of the stomach: natural history, prognostic factors and managementCancer4917787PubMed
27.
Zurück zum Zitat Evans, HL 1985Smooth muscle tumors of the gastrointestinal tract: a study of 56 cases followed for a minimum of 10 yearsCancer56224250PubMed Evans, HL 1985Smooth muscle tumors of the gastrointestinal tract: a study of 56 cases followed for a minimum of 10 yearsCancer56224250PubMed
28.
Zurück zum Zitat Meittinen, M 1988Gastrointestinal stromal tumors. An immunohistochemical study of cellular differentiationAm J Clin Pathol8960110PubMed Meittinen, M 1988Gastrointestinal stromal tumors. An immunohistochemical study of cellular differentiationAm J Clin Pathol8960110PubMed
29.
Zurück zum Zitat Ueyyama, T, Guo, KJ, Hashimoto, H, Daimaru, Y 1992A Clinicopathologic and immunohistochemical study of gastrointestinal stromal tumorsCancer6994755PubMed Ueyyama, T, Guo, KJ, Hashimoto, H, Daimaru, Y 1992A Clinicopathologic and immunohistochemical study of gastrointestinal stromal tumorsCancer6994755PubMed
30.
Zurück zum Zitat Elandson, RA, Klimstra, DS, Woodruff, JM 1996Subclassification of gastrointestinal tumors based on evaluation by electron microscopy and immunohistichemistryUltrastruct Pathol2037393PubMed Elandson, RA, Klimstra, DS, Woodruff, JM 1996Subclassification of gastrointestinal tumors based on evaluation by electron microscopy and immunohistichemistryUltrastruct Pathol2037393PubMed
31.
Zurück zum Zitat Kindblom, LG, Remotti, HE, Aldenborg, F, Meis-Kindblom, JM 1998Gastrointestinal pacemaker cell tumors show phenotypic characteristics of the intestinal cells of CajalAm J Pathol152125968PubMed Kindblom, LG, Remotti, HE, Aldenborg, F, Meis-Kindblom, JM 1998Gastrointestinal pacemaker cell tumors show phenotypic characteristics of the intestinal cells of CajalAm J Pathol152125968PubMed
32.
Zurück zum Zitat Ludwig, DJ, Traverso, LW 1997Gut stromal tumors and their clinical behaviorAm J Surg1733904CrossRefPubMed Ludwig, DJ, Traverso, LW 1997Gut stromal tumors and their clinical behaviorAm J Surg1733904CrossRefPubMed
33.
Zurück zum Zitat Tworek, JA, Goldblum, JR, Weiss, SW, et al. 1999Stromal tumors of the anorectum. A clinicopathological study of 22 casesAm J Surg Pathol2394654CrossRefPubMed Tworek, JA, Goldblum, JR, Weiss, SW,  et al. 1999Stromal tumors of the anorectum. A clinicopathological study of 22 casesAm J Surg Pathol2394654CrossRefPubMed
34.
Zurück zum Zitat Siedal, T, Edvarsson, H 1999Expression of c-kit(CD117) and Ki-67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumorsHistpathology3441624CrossRef Siedal, T, Edvarsson, H 1999Expression of c-kit(CD117) and Ki-67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumorsHistpathology3441624CrossRef
35.
Zurück zum Zitat Wang, X, Mori, I, Tang, W, et al. 2002Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST)Jpn J Clin Oncol3234751CrossRefPubMed Wang, X, Mori, I, Tang, W,  et al. 2002Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST)Jpn J Clin Oncol3234751CrossRefPubMed
36.
Zurück zum Zitat Suster, S, Fisher, C, Moran, CA 1998Expression of Bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surface, and gastrointestinal tractAm J Surg Pathol2286372CrossRefPubMed Suster, S, Fisher, C, Moran, CA 1998Expression of Bcl-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surface, and gastrointestinal tractAm J Surg Pathol2286372CrossRefPubMed
37.
Zurück zum Zitat Noguchi, T, Sato, T, Takeno, S, et al. 2002Biological analysis of gastrointestinal stromal tumorsOncol Rep9127782PubMed Noguchi, T, Sato, T, Takeno, S,  et al. 2002Biological analysis of gastrointestinal stromal tumorsOncol Rep9127782PubMed
38.
Zurück zum Zitat DeMatteo, RP 2002The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571)Ann Surg Oncol98319PubMed DeMatteo, RP 2002The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571)Ann Surg Oncol98319PubMed
39.
Zurück zum Zitat Joensuu, H, Fletcher, C, Dimitrijevic, S, Silberman, S, Roberts, P, Demetri, G 2002Management of malignant gastrointestinal stromal tumoursLancet Oncol365564CrossRefPubMed Joensuu, H, Fletcher, C, Dimitrijevic, S, Silberman, S, Roberts, P, Demetri, G 2002Management of malignant gastrointestinal stromal tumoursLancet Oncol365564CrossRefPubMed
40.
Zurück zum Zitat Hirota, S 1998Gain-of-function mutations of c-kit in human gastrointestinal stromal tumorsScience27957780CrossRefPubMed Hirota, S 1998Gain-of-function mutations of c-kit in human gastrointestinal stromal tumorsScience27957780CrossRefPubMed
41.
Zurück zum Zitat Horiuchi, H, Matsuya, S, Konishi, T 2002Recent progress in gastrointestinal stromal tumor (GIST)Gan To Kagaku Ryoho291495501PubMed Horiuchi, H, Matsuya, S, Konishi, T 2002Recent progress in gastrointestinal stromal tumor (GIST)Gan To Kagaku Ryoho291495501PubMed
42.
Zurück zum Zitat Demetri, GD 2001Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.Semin Oncol28(5 Suppl 17)1926CrossRef Demetri, GD 2001Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.Semin Oncol28(5 Suppl 17)1926CrossRef
43.
Zurück zum Zitat Dagher, R, Cohen, M, Williams, G, et al. 2002Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumorsClin Cancer Res830348PubMed Dagher, R, Cohen, M, Williams, G,  et al. 2002Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumorsClin Cancer Res830348PubMed
44.
45.
Zurück zum Zitat Pidhorecky, I, Cheney, RT, Kraybill, WG, Gibbs, JF 2000Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and managementAnn Surg Oncol770512PubMed Pidhorecky, I, Cheney, RT, Kraybill, WG, Gibbs, JF 2000Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and managementAnn Surg Oncol770512PubMed
Metadaten
Titel
Evaluation of Prognosis for Malignant Rectal Gastrointestinal Stromal Tumor by Clinical Parameters and Immunohistochemical Staining
verfasst von
Chung Rong Changchien, M.D.
Meng-Chi Wu, M.D.
Wen-Sy Tasi, M.D., Ph.D.
Reiping Tang, M.D.
Jy-Ming Chiang, M.D.
Jinn-Shiun Chen, M.D.
Shiu-Feng Huang, M.D.
Jeng-Yi Wang, M.D.
Chien-Yuh Yeh, M.D.
Publikationsdatum
01.11.2004
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 11/2004
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-004-0687-8

Weitere Artikel der Ausgabe 11/2004

Diseases of the Colon & Rectum 11/2004 Zur Ausgabe

OriginalPaper

The Authors Reply

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Recycling im OP – möglich, aber teuer

05.05.2024 DCK 2024 Kongressbericht

Auch wenn sich Krankenhäuser nachhaltig und grün geben – sie tragen aktuell erheblich zu den CO2-Emissionen bei und produzieren jede Menge Müll. Ein Pilotprojekt aus Bonn zeigt, dass viele Op.-Abfälle wiederverwertet werden können.

Im OP der Zukunft läuft nichts mehr ohne Kollege Roboter

04.05.2024 DCK 2024 Kongressbericht

Der OP in der Zukunft wird mit weniger Personal auskommen – nicht, weil die Technik das medizinische Fachpersonal verdrängt, sondern weil der Personalmangel es nötig macht.

Nur selten Nachblutungen nach Abszesstonsillektomie

03.05.2024 Tonsillektomie Nachrichten

In einer Metaanalyse von 18 Studien war die Rate von Nachblutungen nach einer Abszesstonsillektomie mit weniger als 7% recht niedrig. Nur rund 2% der Behandelten mussten nachoperiert werden. Die Therapie scheint damit recht sicher zu sein.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.